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Abstract
Background: Three IL-10 gene promoter single nucleotide polymorphisms -1082G > A, -819C > T and -592C > A
and the haplotypes they define in Caucasians, GCC, ACC, ATA, associated with different IL-10 production rates, have
been linked to schizophrenia in some populations with conflicting results. On the basis of the evidence of the sex-
dependent effect of certain genes in many complex diseases, we conducted a sex-stratified case-control
association study to verify the linkage of the IL-10 gene promoter SNPs and haplotypes with schizophrenia and the
possible sex-specific genetic effect in a Spanish schizophrenic population.
Methods: 241 DSM-IV diagnosed Spanish schizophrenic patients and 435 ethnically matched controls were
genotyped for -1082G > A and -592C > A SNPs. Chi squared tests were performed to assess for genetic association
of alleles, genotypes and haplotypes with the disease.
Results: The -1082A allele (p = 0.027), A/A (p = 0.008) and ATA/ATA (p = 0.003) genotypes were significantly
associated with schizophrenia in females while neither allelic nor genotypic frequencies reached statistical
significance in the male population.
Conclusions: Our results highlight the hypothesis of an imbalance towards an inflammatory syndrome as the
immune abnormality of schizophrenia. Anyway, a better understanding of the involvement of the immune system
would imply the search of immune abnormalities in endophenotypes in whose sex and ethnicity might be
differential factors. It also reinforces the need of performing complex gene studies based on multiple cytokine
SNPs, including anti and pro-inflammatory, to clarify the immune system abnormalities direction in the etiology of
schizophrenia.
Background
There is consistent evidence pointing the immune system
as playing an important role in both etiology and patho-
physiology of schizophrenia [1,2]. A key element of this
immune theory is the significant increase in the levels of
some Th1 (T helper cell type 1) cytokines such as IL-1,
IL-6 or TNF (tumor necrosis factor) in plasma, or even
cerebrospinal fluid, found in schizophrenic patients, and
abnormal levels of Th2 (T helper cell type 2) cytokines
such as IL-10 [3]. It is well documented that some cyto-
kines production is regulated at the transcriptional level,
which may indicate that the immune alterations in schi-
zophrenia could have a genetic origin [4].
This occurs with IL-10 in which three gene promoter sin-
gle nucleotide polymorphisms (SNPs), -1082G > A, -819C
>Tand -592C > A, define three haplotypes in Caucasians,
GCC, ACC, ATA, associated to different IL-10 production
rates [5]. Both IL-10 SNPs and haplotypes have been
reported to be in linkage disequilibrium with schizophrenia
in some populations [3,6,7].
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association of certain genes with many complex diseases
including schizophrenia [8] where sex differences have
been described for genes such as RELN [9], XBP1 [10]
Nogo [11] and IL-10 [6].
Thus, the aims of this study were to verify the linkage
of the IL-10 gene promoter SNPs and haplotypes with
s c h i z o p h r e n i aa n dt oe x p l o r eap u t a t i v es e x - s p e c i f i c
genetic association of these polymorphisms in a Spanish
schizophrenic population.
Methods
Subjects
241 Caucasian (64% males) unrelated Spanish schizophre-
nic adult patients, mean age (± Standard Deviation-SD-)
45 ± 13 years, were enrolled in the study. DSM-IV diagno-
sis was provided using a brief structured psychiatric inter-
view, the Spanish version of the Mini International
Neuropsychiatric Interview version 4.4 (MINI 4.4) [12].
435 unrelated adult (47% males), mean age ( ± SD) 38 ±
18 years, Caucasian, Spanish healthy volunteers, with no
clinical history of chronic illness, were enrolled in the
study from 3 different centers.
The study protocol was reviewed and approved by
Ethics Committees of all participating centers and con-
ducted according to the tenets of the Declaration of
Helsinki. Before enrolment, all participating subjects
signed an informed consent form after the study objec-
tives and procedures were fully explained.
DNA extraction and genotyping
G e n o m i cD N Aw a se x t r a c t e df r o m7m lo fp e r i p h e r a l
blood samples using both automatic DNA extractors
(BioRobot EZ1, QIAGEN, Hilden, Germany; MagNA Pure
System, Roche Applied Science) and conventional salting-
out methods. DNA concentration and quality of samples
were assessed spectrophotometrically (NanoDrop
® ND-
1000 Spectrophotometer, Wilmington DE, USA).
Genotyping of -1082G > A SNP was performed through
ap h a r m a c o g e n e t i ct o o l ,PHARMAchip
® (Progenika
Biopharma, Spain) that includes genetic variants involved
in therapeutic outcome, which methodology has been
described elsewhere [13].
IL-10 -592C > A was genotyped with a TaqMan
® Pre-
Designed SNP genotyping assay (c__747363_10) accord-
ing to the TaqMan Allelic Discrimination technology
[14] using the ABI Prism 7000 (Applied Biosystems,
Foster City, CA, USA).
Since there were two different genotyping methods,
both results were further confirmed by genotyping 100
randomly selected samples for the three IL-10 promoter
SNPs by direct DNA sequencing, using a BigDye Termi-
nator Cycle Sequencing Kit and an ABI Prism 3130xl
DNA sequencer (Applied Biosystems, Foster City, CA,
USA). Therefore, the -819C > T SNP was also assessed in
these samples. Primers used for the PCR reaction were
5’GACAACACTACTAAGGCTTCTTTGG3’-forward-
and 5’TGTAGGAAGCCAGTCTCTGGA3’-reverse-
obtaining a PCR product of 540 bp. Cycling conditions
were 95ºC for 10 minutes, followed by 35 cycles of 95ºC
for 30s, 59ºC for 30s and 72ºC for 40s, with a final elon-
gation of 10 minutes at 72ºC.
Data analysis
-1082G > A variant results were translated into geno-
types by Progenika. Similarly, -592C > A results were
processed by the ABI Prism 7000 Allelic Discrimination
Analysis software. Since the three IL-10 gene promoter
SNPs are in linkage disequilibrium in Caucasians and
only three haplotypes have been described (GCC, ACC,
ATA), they were constructed according to SNPs at posi-
tions -1082 and -592 as previously described by Ortiz
et al [15].
Allele, genotype and haplotype (allelic and genotypic)
frequencies for both cases and controls were calculated
and Hardy-Weinberg equilibrium was estimated. A sex-
stratified case-control analysis was performed to find
out the possible sex-specific association of IL-10 gene
promoter SNPs to schizophrenia.
Statistical analysis
Student T test was performed to assess for possible sig-
nificant differences in age between cases and controls
globally and in each sex group. Pearson’s chi squared test
was used to compare allele, genotype or haplotype fre-
quencies between schizophrenics and controls in male
and female populations. Test for equality of proportions
was used to find possible differences in the incidence of
ATA between schizophrenic and healthy females. The
odds ratio (OR), with its 95% confidence interval (95%
CI), was the measure of the strength of association
between alleles, genotypes and haplotypes with schizo-
phrenia in the two groups. Statistical analysis was carried
using R.2.10.0 software (from R Project for Statistical
Computing -http://www.r-project.org-).
Results
241 patients and 435 controls were finally genotyped for
SNP -1082G > A. The totality of DNA control samples
could not be genotyped for -592C > A. Thus, IL-10
-592C > A variant and IL-10 gene promoter haplotypes
could be determined in 241 patients and 381 controls.
The results of -1082G > A and -592C > A sequencing
yielded a 98% of concordance, since there were two dis-
crepancies between methods for both variants. -1082G >
A, -592C > A genotypes and haplotype distributions
were in Hardy-Weinberg equilibrium at the 5% signifi-
cant level.
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-592C >A allelic and genotypic frequencies in the sex-
stratified analysis and the mean age of each population.
Mean age between cases and controls resulted signifi-
cantly different globally (p = 0.000) and stratifying by
sex (p = 0.002 in female case-control group and p =
0.000 in male case-control group) Neither allelic nor
genotypic frequencies reached the statistical significance
in the association in the male population while female
schizophrenics had a statistically significant higher inci-
dence of allele -1082A than the controls as well as geno-
type -1082A/A.
-592C>Aallelic and genotypic distribution was simi-
lar between schizophrenic and healthy males while,
again, there was a statistically significant association of
genotype A/A with schizophrenia in the females.
Table 2 shows the analysis of haplotypes stratified by
sex. While allelic frequencies were similar in cases and
controls in both groups, when comparing genotypic dis-
tribution, it differed significantly in schizophrenic
females. Significant trends were observed for genotypes
ATA/ATA and GCC/ATA. Frequencies of carrying 2, 1
or no copies of ATA in females, and the resultant p-
value of the test for equality of proportions, are sum-
marized in table 3 which shows a statistically significant
higher incidence of 2 ATA in the schizophrenic females
compared to the healthy ones. The ORs of association
of 2 ATA versus 1 or no copies of ATA and, also, of 1
ATA versus 0 ATA (table 4) points that carrying 2
copies of ATA was the higher statistically significant risk
factor when comparing to 1 or no copies.
Discussion
At the genetic level, many components of the immune
system have been linked to schizophrenia, through can-
didate-gene [3,6], pathway-based [2] and genome-wide
association [1] approaches that have yielded solid evi-
dence of the immune system involvement in schizophre-
nia. Specifically the recent report by Sun highlights the
IL-10 signaling as a candidate pathway in schizophrenia
[2].
Since first described by Bochio Chiavetto [3] the link-
age between -1082G of the IL-10 gene promoter variant
with schizophrenia in Italians, several studies have tried
to replicate this association in various populations with
conflicting results. While confirmed in a recent study
[6], this trend has not been observed in other popula-
tions [16] or contradictory findings have been reported
[7,17].
This study addresses the significant association of IL-10
-1082A allele with schizophrenia females. These results
contrast to those reported in Italians [3] and Polish [6]
case-control studies that found the G allele significantly
increased in the schizophrenia group. Regarding the
report of Bochio Chiavetto [3], the allelic frequencies of
the population selected as the reference are significantly
different to data published in Caucasians (TSI or CEU
populations of HapMap) suggesting that the association
m a yb ed u et oab i a s e ds e l e c t i on of the control popula-
tion (most likely an incorrect matching with the cases).
In the second report only paranoid schizophrenics were
included in the study and significant association was only
found in males [6].
Table 1 Allelic and genotypic frequencies of -1082G > A and -592C > A IL-10 gene promoter variants
Males Females
Control
(n = 201)
Schizophrenia
(n = 153)
OR (95%CI) P Control
(n = 234)
Schizophrenia
(n = 88)
OR (95% CI) P
Age (years) 37 ± 18 45 ± 13 0.000* 39 ± 18 46 ± 13 0.002*
-1082G > A
Allelic frequencies
n% n % p n% n %
G 164 40.8% 111 36.3% 1.21 (0.88-1.66) 0.252 198 42.3% 57 32.4% 1.53 (1.04-2.25) 0.027*
A 238 59.2% 195 63.7% 270 57.7% 119 67.6%
Genotypic frequencies
G/G 38 18.9% 23 15.0% 0.502 33 14.1% 11 12.5% 0.008*
G/A 88 43.8% 65 42.5% 132 56.4% 35 39.8%
A/A 75 37.3% 65 42.5% 69 29.5% 42 47.7%
-592 C > A
Allelic frequencies
n % n % OR (95%CI) p n % n % OR (95% CI) p
C 274 75.7% 227 72.8% 1.11 (0.77-1.60) 0.618 298 74.5% 123 69.1% 0.76 (0.51-1.15) 0.213
A 88 24.3% 79 25.3% 102 25.5% 53 29.8%
Genotypic frequencies
C/C 110 60.8% 84 53.8% 0.134 106 53.0% 47 52.8% 0.004*
C/A 54 29.8% 59 37.8% 86 43.0% 29 32.6%
A/A 17 9.4% 10 6.4% 8 4.0% 12 13.5%
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GCC in Italians [3] or GTA in Turkish [18], both asso-
ciated with high IL-10 production, have been linked to
the disease and although high plasma levels of this cyto-
kine have been reported in some studies associated to
schizophrenia, it has not always been replicated [19].
Furthermore, in a recent meta-analysis in which the
effect of 10 cytokines plasma levels in schizophrenia was
assessed, including IL-10, only significant trends have
been observed for IL-1RA, sIL-2R and IL-6, providing
evidence of an inflammatory syndrome in schizophrenia
[20].
This study also describes for the first time the associa-
tion of IL-10 gene promoter ATA/ATA low IL-10 produ-
cing genotype linked to schizophrenia in Spanish
females. Our results indicate that being homozygote for
ATA is the main risk factor for schizophrenia in Spanish
females compared to ATA heterozygosity or other geno-
types not including ATA.
There is evidence of the role of IL-10 in the neurodeve-
lopmental abnormalities found in schizophrenia [21]. IL-
10 is an anti-inflammatory cytokine that regulates the
inflammatory response, by inhibiting pro-inflammatory
cytokine production [22], and it is constitutively
expressed during fetal brain development in humans
[23]. Meyer et al suggest that the genetically determined
differences in IL-10 production could lead to behavioral
abnormalities in the adulthood after prenatal immune
challenge or innate immune imbalances. They also
pointed out that not only an excess of pro-inflammatory
cytokines but also an imbalance between both classes of
cytokines during development might alter normal brain
functions in adult life [21].
Our findings are also supported by a recent report by
Sharma et al, which describe a linkage between the ATA
haplotype and differential repression of IL-10 produc-
tion, under infectious conditions, in human trophoblast
[24].
On the other hand, there are several evidences of gen-
der differences in schizophrenia regarding incidence, age
of onset, disease course, therapeutic response, social and
intellectual functioning and brain abnormalities [25].
Additionally, a sex-specific risk of some genes to certain
diseases, including schizophrenia [8] with a number of
loci involved, has been described [6,10,11]. There are var-
ious possible mechanisms for sex differences in gene
expression, including imprinting or hormonal effects
[26]. In the case of IL-10, or genes encoding cytokines in
general, estrogen receptors are found in certain immune
cells [27] responsible for IL-10 production. Direct estro-
gen-mediated modulation of this immune cell activity
leads to changes in cytokine production [28] and can
Table 2 Allelic and genotypic frequencies of IL-10 gene promoter haplotypes in schizophrenic and healthy males and
females
Males Females
Control
(n = 181)
Schizophrenia
(n = 153)
Control
(n = 200)
Schizophrenia
(n = 88)
Allelic frequencies n % n % p n % n % p
GCC 146 40.3% 111 36.3% 0.557 167 41.8% 58 33.0% 0.124
ACC 126 34.8% 115 37.6% 134 33.5% 65 36.9%
ATA 90 24.9% 80 26.1% 99 24.8% 53 30.1%
Genotypic frequencies
GCC/GCC 33 18.2% 23 15.0% 0.382 26 13.0% 12 13.6% 0.003*
GCC/ACC 48 26.5% 39 25.5% 60 30.0% 20 22.7%
GCC/ATA 32 17.7% 26 17.0% 55 27.5% 14 15.9%
ACC/ACC 28 15.5% 22 14.4% 22 11.0% 16 18.2%
ACC/ATA 22 12.2% 32 20.9% 30 15.0% 13 14.8%
ATA/ATA 18 9.9% 11 7.2% 7 3.5% 13 14.8%
Table 3 ATA frequencies in the female subgroup
FEMALES
Control
(n = 200)
Schizophrenia
(n = 88)
Equality of
proportions
Number of ATA alleles n % n % p
2 ATA 7 3.5% 13 14.8% 0.001*
1 ATA 85 42.5% 27 30.7% 0.078
0 ATA 108 54.0% 48 54.5% 1
2 ATA means homozygosity of this allele, 1 ATA heterozygosity and 0 ATA
means no copy of ATA in the genotype.
Table 4 ORs of ATA as risk factor for schizophrenia in
females
OR 95%CI p-value
2 ATA vs. 1 ATA 5.85 1.91-18.90 0.000*
2 ATA vs. 0 ATA 4.18 1.43-13.08 0.002*
1 ATA vs. 0 ATA 0.71 0.39-1.28 0.231
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females.
Conclusions
Although further exploration of immune system involve-
ment in schizophrenia is needed, our results highlight
the previously described hypothesis of an imbalance
towards a pro-inflammatory syndrome as the immune
abnormality of schizophrenia [20]. Anyway, it should be
noted that immune abnormalities are found only in a
relatively small subgroup of patients [21]. A better
understanding of the involvement of the immune system
in schizophrenia would imply the search of immune
abnormalities in what has been called endophenotypes,
intermediate phenotypes between the clinical entity and
susceptibility genes and so, presumably closer to rele-
vant genes [29] in whose sex and ethnicity may be dif-
ferential factors. Additionally, the results of this study
reinforce the need of performing complex gene studies
based on multiple cytokine SNPs, including anti- and
pro-inflammatory, to clarify the immune system
abnormalities direction in the etiology of schizophrenia.
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